Calvin Scheller
Research Analyst
Introduction
Glucagon-like peptide-1 (GLP-1) has emerged as a key player in the field of metabolic health, with its implications extending beyond glucose regulation to areas such as weight management and diabetes treatment. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which means it is a type of hormone that is released from the gut in response to food intake.
This incretin hormone is secreted by enteroendocrine cells in the gastrointestinal tract in response to nutrient intake, particularly carbohydrates, amino acids, short chain fatty acids and fats. Its physiological effects are mediated through interactions with GLP-1 receptors (GLP-1R) expressed on various target tissues, including pancreatic beta cells, alpha cells, the central nervous system, and peripheral tissues.
In recent years, the therapeutic potential of GLP-1 and GLP-1 receptor agonists has gained significant attention, leading to the development of novel medications for weight loss and diabetes management.
History and the current state of affairs
GLP-1 (glucagon-like peptide-1) was initially derived from the venom of the Gila monster, a large lizard native to the southwestern United States and Mexico. Researchers discovered that a peptide in the venom, known as exendin-4, shared a similar structure to human GLP-1 and had potent effects on blood glucose regulation. This discovery led to the development of exenatide, the first GLP-1 receptor agonist (GLP-1RA) used as a medication. However, exenatide had a relatively short half-life, requiring frequent injections to maintain its efficacy, which limited its practicality and patient compliance (1).
To improve the pharmacokinetic properties of GLP-1RAs, scientists made several modifications to extend their half-life and enhance their effectiveness. One significant advancement was the development of modified GLP-1 molecules that resist enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), an enzyme that rapidly breaks down endogenous GLP-1. This led to the creation of longer-acting GLP-1RAs that could be administered less frequently (2).
Another key modification involved attaching fatty acid chains to the GLP-1 molecule, which binds to albumin in the bloodstream, thereby slowing its clearance and prolonging its action. The most common GLP-1 receptor agonists (GLP-1RAs) used in clinical practice contain the active ingredient liraglutide and semaglutide, which bind to and activate the GLP-1 receptor (3).
These modifications have revolutionized the treatment of type 2 diabetes and obesity by providing more effective and convenient therapeutic options. Semaglutide, for example, not only improves blood glucose levels but also promotes weight loss and has shown cardiovascular benefits, making it a highly valuable addition to the array of GLP-1 RA medications available today (4).
GLP-1RAs were initially developed and approved for the treatment of type 2 diabetes (5). GLP-1 plays a crucial role in glucose homeostasis by stimulating insulin secretion, inhibiting glucagon release, slowing gastric emptying, and reducing appetite. Traditional use of GLP-1RAs in diabetes management involves improving glycemic control by enhancing the secretion of insulin in the pancreas, and via weight reduction and its anti-inflammatory actions, improving insulin sensitivity, without causing significant hypoglycemia.
Over time, it was observed that GLP-1RAs also had significant effects on weight reduction. Patients treated with these medications often experienced substantial weight loss, which led researchers to investigate the potential of GLP-1RAs for the treatment of obesity. The mechanism behind this weight loss includes appetite suppression, delayed gastric emptying, and a decrease in food intake. These effects are mediated through GLP-1 receptors in the brain and gut, which influence satiety and food consumption (6).
As a result of these findings, GLP-1RAs have been increasingly recognized and utilized in the management of obesity, particularly in patients who are overweight or obese and may or may not have diabetes. Semaglutide, for instance, has been approved not only for glycemic control in diabetes but also as a weight management therapy in higher doses. The dual benefits of improved blood sugar control and weight loss make GLP-1RAs a valuable option for treating both type 2 diabetes and obesity, addressing two major interrelated health concerns. For example, Semaglutide, marketed under the brand names Ozempic and Wegovy, is used for different purposes and has distinct dosage regimens based on its intended use. Ozempic is primarily prescribed for the management of type 2 diabetes, while Wegovy is indicated for weight management in individuals with obesity or overweight-related health conditions.
Ozempic is administered as a once-weekly injection for glycemic control in type 2 diabetes patients. The typical starting dose is 0.25 mg once a week for four weeks, which is then increased to 0.5 mg once a week. If further glycemic control is needed, the dose can be increased to a maximum of 1 mg once a week (7).
Wegovy, on the other hand, is specifically formulated for chronic weight management. The dosing regimen for Wegovy involves a more gradual titration to reach the maintenance dose. It starts with a dose of 0.25 mg once weekly for the first month, followed by an increase to 0.5 mg for the second month, 1 mg for the third month, 1.7 mg for the fourth month, and finally reaching the maintenance dose of 2.4 mg once weekly from the fifth month onwards (8).
While both Ozempic and Wegovy contain the same active ingredient, semaglutide, their dosing schedules and target populations differ.
Overall, GLP-1 and GLP-1 receptor agonists represent a paradigm shift in the management of metabolic disorders, offering comprehensive and effective approaches to improving glucose control, promoting weight loss, and reducing cardiovascular risk. With ongoing research and development, the therapeutic potential of GLP-1-based medications continues to expand, offering new hope for individuals living with obesity and diabetes.
In the United States, the use of GLP-1 receptor agonists (GLP-1 RAs) has seen a significant increase in recent years, reflecting their growing role in managing obesity and type 2 diabetes. Studies in 1019 suggest more than 10% of diabetics in the US are using semaglutide, and unfortunately a shortage of these medications is now becoming a real phenomenon that we are facing (9).
Anatomy
L-cells are predominantly located in the distal ileum and colon, with sparse distribution in the duodenum and jejunum.
GLP-1 is synthesized as a larger precursor molecule called preproglucagon within the enteroendocrine L-cells. This precursor undergoes post-translational processing, first cleaved into proglucagon and subsequently into several biologically active peptides, including GLP-1.
Once synthesized, GLP-1 is stored in secretory granules within the cytoplasm of L-cells. These granules contain a pool of mature, bioactive GLP-1 ready for secretion. The storage of GLP-1 in secretory granules allows for rapid release in response to physiological stimuli, such as nutrient intake (10).
In essence, GLP-1 secretion occurs when the right nutrients are found in the right place at the right time. Multiple different molecules can stimulate the release of GLP-1 by directly interacting with the L-Cells. These include glucose, Amino acids, fatty acids, curcumin, capsaicin, allulose, and other sweet-tasting molecules.
Dietary Modulation of GLP-1
Glucose
The GLP-1-secreting cells contain specific glucose transport mechanisms that are not insulin-dependent. This is a seemingly meaningless but very impactful fact. The reason being, that insulin secretion does not occur until after food has exited the small intestine. If GLP-1-producing cells require insulin to stimulate their uptake of glucose, the glucose would have more than likely exited their intestinal tract by the time insulin production was simulated. Moreover, GLP-1 is a very important stimulator of GLP-1 production in and of itself, thus GLP-1 typically precedes insulin production, rather than vice versa. Luckily, our physiology is eloquently designed so that the glucose transport proteins that populate the intestinal L-cells are glucose-independent transporters. The specific glucose transported located within the L-cells includes mainly SGLT2 (11) and the GLUT 2 transporter (12).
GLUT 2 Glucose Uptake
GLUT-2 receptors are essentially permanently embedded in the membrane allowing for glucose to enter the cell in a dose-dependent manner depending on its concentration within the small intestine (13).
SGLT Glucose uptake
The transport cycle of the SGLT (Sodium-Glucose Transporter) protein begins when sodium ions attach to their specific binding sites on the SGLT. This binding enhances the transporter’s ability to bind glucose. Sodium is drawn to the transporter due to the electrochemical gradient created by the Na+/K+ ATPase pump, which actively moves sodium out of the cell and potassium into the cell.
Once sodium is bound, glucose molecules then attach to their own sites on the SGLT. This interaction triggers a structural shift in the transporter, changing its shape to allow the sodium and glucose to move across the cell membrane.
Inside the cell, where sodium concentration is lower due to the Na+/K+ ATPase activity, sodium ions detach from the transporter. This reduction in sodium binding lowers the transporter’s affinity for glucose, leading to the release of glucose into the cell’s interior.
After the sodium and glucose are released, the SGLT returns to its original outward-facing position, ready to start the cycle again with new sodium and glucose molecules (14).
Glucose Stimulation of GLP-1 Release
Within the L-cells, glucose is used to generate ATP. Higher glucose levels in the gastrointestinal tract, particularly in the more distal regions, lead to increased ATP production within these cells. This rise in ATP levels affects potassium channels on the cell membrane by causing them to close. As a result, potassium accumulates inside the cell, which increases the cell’s voltage.
In addition to the potassium channels, there are also what are referred to as voltage-gated calcium channels. As the name implies, these cells are highly responsive to an increase in cell charge/voltage, and the potassium buildup causes them to open. The result is the influx of calcium into the cell.
Calcium plays a crucial role in the release of GLP-1 from the vesicles inside the L-cells. It facilitates the fusion of these vesicles with the cell membrane by interacting with SNARE proteins, which are essential for this process. The calcium-dependent binding of SNARE proteins allows the vesicle to merge with the cell membrane, releasing GLP-1 into the bloodstream.
Protein
The main peptide/amino acid sensors within the L-cells include the Calcium-Sensing Receptor (CaSR) and Peptide transporter 1 (PEPT1) (17).
Calcium-Sensing Receptor (CaSR)
The Calcium-Sensing Receptor (CaSR) is responsible for detecting and responding to extracellular calcium levels, as well as to other divalent and trivalent cations and certain amino acids, particularly aromatic ones (11). The presence of peptides and amino acids and calcium activate this receptor and stimulate GLP-1 release and reproduction (18).
PEPT1
This receptor functions via direct and indirect mechanisms. Directly, the PEPT1 operates by coupling the transport of peptides with hydrogen protons, which increases intracellular voltage (19)
Moreover, the increase in intracellular amino acids further stimulates CaSr proteins (20).
Amino acid oxidation
Glutamine appears to be especially potent at stimulating GLP-1 production (22).
This is likely the process of glutaminolysis, which is the process by which glutamine is readily turned into ATP, which increases intracellular ATP and acts via the same mechanism of action as glucose (23). Many other amino acids including the BCAA’s, cysteine, methionine, etc., can also be converted into ATP, increasing intracellular ATP, which as discussed stimulates GLP-1 release (22).
Fat and short-chain fatty acids (SCFA)
The Free Fatty Acid Receptor (FFAR) family comprises several G protein-coupled receptors (GPCRs) that respond to free fatty acids (FFAs) of different chain lengths. These receptors are crucial in regulating energy metabolism and have become significant targets for potential treatments of metabolic disorders such as diabetes, obesity, and inflammatory diseases. The main receptors in this family that are pertinent to human physiology are FFAR1 (also known as GPR40), FFAR2 (GPR43), FFAR3 (GPR41), and FFAR4 (GPR120) (25).
1. FFAR1 (GPR40)
- Ligands and Activation: FFAR1 is activated by medium to long-chain fatty acids. This receptor has a high affinity for saturated and unsaturated fatty acids such as linoleic acid, alpha-linolenic acid, and palmitic acid(26).
2. FFAR2 (GPR43) and FFAR3 (GPR41)
- Ligands and Activation: These receptors are primarily activated by short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate, which are produced by bacterial fermentation of dietary fibers in the colon (28).
3. FFAR4 (GPR120)
- Ligands and Activation: FFAR4 is activated by long-chain omega-3 fatty acids, such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)(30).
Curcumin
Curcumin, the primary bioactive compound in turmeric, has been shown to enhance intracellular levels of cyclic adenosine monophosphate (cAMP), which plays a key role in stimulating the release of GLP-1. Although the precise mechanisms are not fully elucidated, several theories suggest how curcumin achieves this effect. One proposed mechanism is the inhibition of phosphodiesterases (PDEs), the enzymes that typically break down cAMP. By blocking PDE activity, curcumin helps to maintain higher concentrations of intracellular cAMP, leading to greater GLP-1 release(32,33). Additionally, curcumin may influence adenylate cyclase (AC) activity, the enzyme responsible for producing cAMP from ATP, either directly or indirectly. This activation may occur through the stimulation of FFAR1 and FFAR4 receptors, further promoting increased cAMP production (34,35).
The rise in cAMP levels subsequently activates protein kinase A (PKA). This activation occurs when cAMP binds to PKA’s regulatory subunits, causing them to detach from the catalytic subunits. Once activated, PKA can phosphorylate various intracellular proteins, including those involved in the synthesis and secretion of GLP-1.
Capsaicin
Capsaicin, the active component in spicy foods, is responsible for the burning and pain sensations associated with “heat.” It exerts its effects primarily by activating transient receptor potential vanilloid 1 (TRPV1) receptors, which are present on various cells throughout the body, including enteroendocrine L-cells that secrete GLP-1. TRPV1 receptors function as calcium channels. When capsaicin activates these receptors, it induces a conformational shift that opens the central pore of the channel, allowing calcium ions to flow through. This increase in intracellular calcium levels subsequently promotes the release of GLP-1 into the bloodstream (36).
Other Polyphenols
Polyphenols, which are a wide range of plant-derived compounds, have garnered attention for their potential health benefits, particularly their impact on glucagon-like peptide-1 (GLP-1) production. Research has shown that several polyphenols can enhance GLP-1 levels. These include Hispidulin (38), Grifolic acid methyl ether (39), Grifolic acid (39), Genistein (40), EGCG (41), Delphinidin 3-rutinoside (42), Curcumin (34,35), feruloyl quinic acid (43), lignans (44), Caffeic acid (45), and Caffeoylquinic acid (45), among others that may still be unidentified. These compounds influence a range of signaling pathways, which contribute to their effect on GLP-1 production.
1. Interaction with G Protein-Coupled Receptors (GPCRs):
Polyphenols interact with G protein-coupled receptors (GPCRs) on enteroendocrine L-cells, which are crucial for GLP-1 production. Activation of these receptors by polyphenols initiates signaling pathways that stimulate GLP-1 secretion (46). For instance, epigallocatechin gallate (EGCG) from green tea (39) and curcumin from turmeric (34,35) activate GPCRs like GPR40 and GPR120, promoting GLP-1 release.
2. Modulation of Enzyme Activity:
Certain polyphenols have the ability to influence the enzymes that regulate GLP-1 production and breakdown. For instance, compounds such as myricetin, hyperoside, narcissoside, cyanidin 3-O-glucoside, and isoliquiritigenin, along with curcumin, syringic acid, and resveratrol, can inhibit dipeptidyl peptidase-4 (DPP-4). DPP-4 is an enzyme that degrades GLP-1, and by inhibiting its activity, these polyphenols help extend the half-life of GLP-1 and amplify its effects (47, 48, 49). Furthermore, some polyphenols may activate adenylate cyclase (AC), the enzyme that converts ATP into cyclic adenosine monophosphate (cAMP). Elevated levels of cAMP can enhance GLP-1 secretion from L-cells (as discussed above).
3. Short-chain fatty acids
Polyphenols can be fermented by gut microbiota into intermediate products like phenolic acids, which are further fermented to produce short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. Polyphenols also exhibit prebiotic effects, promoting the growth of beneficial gut bacteria like Bifidobacteria and Lactobacilli, which produce ample SCFAs (50).
Allulose
Unfortunately, there is a paucity of literature depicting the mechanism, however, it is abundantly clear that allulose stands out among sweeteners in its capacity to stimulate GLP-1 secretion (51). I personally have a few hypotheses:
- Allulose is in fact about 70% absorbed in the small intestine (52) using the GLUT2 receptor, thus it could potentially modulate intracellular cAMP or electrolyte levels similar to other nutrients, modulating the release of GLP-1.
- The other ~30% of ingested allulose is fermented by the gut bacteria, increasing the production of SCFA (53), which we know increases GLP-1 production.
- Allulose, and other sweet substances such as fructose and other artificial sweeteners for that matter, activate the T1R2/T1R3 receptors located on the surface of intestinal L-cells. These receptors appear to increase intracellular cAMP AND increase glut 2 activity and glucose uptake, both of which would seemingly increase GLP-1 secretion (54).
There are a myriad of other things that can increase GLP-1 secretion, however, the above-mentioned items appear to be the most notorious and well-studied.
Bile acids
Bile acids play a vital role not only in the digestion of lipids but also as signaling molecules that impact various metabolic processes, including the secretion of incretin hormones such as GLP-1. Produced in the liver from cholesterol and stored in the gallbladder, bile acids are released into the small intestine in response to dietary fat intake. This release helps to emulsify fats, thereby aiding their digestion and absorption (55). Bile acids stimulate GLP-1 secretion primarily through their interaction with TGR5, a G protein-coupled receptor expressed on L-cells. When bile acids bind to TGR5, they activate the receptor and stimulate intracellular signaling cascades that increase GLP-1 release.
Stay tuned for Part 2!
Citations
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219279/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145895/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149770/
- https://www.ncbi.nlm.nih.gov/books/NBK603723/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085572/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046996/#:~:text=GLP%2D1RA%20inhibits%20glucagon%20secretion,improvement%20and%20body%20weight%20loss.
- https://www.ozempic.com/how-to-take/ozempic-dosing.html
- https://www.wegovy.com/taking-wegovy/dosing-schedule.html#:~:text=Wegovy%C2%AE%20comes%20in%205,mg%20for%20your%20maintenance%20dose.
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796881/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280675/#:~:text=Oral%20glucose%20absorption%20induces%20GLP,L%2Dcells%20into%20intestinal%20capillaries
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462918/
- https://www.sciencedirect.com/science/article/pii/S2212877816302162
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10850595/
- https://www.ncbi.nlm.nih.gov/books/NBK576405/
- https://www.dovepress.com/pharmacological-and-clinical-studies-of-medicinal-plants-that-inhibit–peer-reviewed-fulltext-article-DDDT
- https://link.springer.com/chapter/10.1007/978-3-031-34229-5_4
- https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2017.00085/full
- https://www.nature.com/articles/s41598-022-12737-w
- https://www.sciencedirect.com/science/article/abs/pii/S0168365996015854
- https://www.mdpi.com/2072-6643/13/3/883
- s://www.nature.com/articles/s41392-023-01569-3
- https://academic.oup.com/endo/article/152/2/405/2457001?login=true
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225500/
- https://www.nature.com/articles/s41392-023-01569-3
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222138/
- https://pubmed.ncbi.nlm.nih.gov/19460454/
- https://www.sciencedirect.com/science/article/abs/pii/S0006295222002441
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344995/
- https://www.mdpi.com/1422-0067/23/6/3303
- https://pubmed.ncbi.nlm.nih.gov/20471368/
- https://www.sciencedirect.com/science/article/pii/S016561471730127X
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087130/
- https://pubmed.ncbi.nlm.nih.gov/33551001/#:~:text=Conclusion%3A%20The%20 present%20results%20 suggest,%2F PKA%2FA MPK%20 signaling%20 pathway.
- https://pubmed.ncbi.nlm.nih.gov/23660191/
- https://pubmed.ncbi.nlm.nih.gov/27990751/
- https://www.sciencedirect.com/science/article/abs/pii/S0143416017301720
- https://www.sciencedirect.com/science/article/abs/pii/S0143416017301720
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473469/
- https://pubmed.ncbi.nlm.nih.gov/19471906
- https://pubmed.ncbi.nlm.nih.gov/30784939
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566026/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427495/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462761/
- https://pubmed.ncbi.nlm.nih.gov/24269245/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866283/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134086/
- https://www.nature.com/articles/s41598-019-52088-7#:~:text=After%20screening%2C%20curcumin%2C%20syringic%20acid,potential%20 inhibition%20of%20 DPP%20IV.
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145895/
- https://www.sciencedirect.com/science/article/pii/S1756464620303935
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747136/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071322/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467252/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071329/
- https://www.sciencedirect.com/science/article/pii/S0022316622006162
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811459/#:~:text=Bile%20 acids%20are%20 potent%20%E2%80%9c Digestive,turnover%20of%20 cholesterol%20(1).
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333617/#:~:text=Given%20that%20 crosstalk%20between%20 FXR,obesity%20and%20 type%20II%20 diabetes.
- https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.678055/full



